Sugi Predict

Sugi Predict / Targets / DYRK1A

DYRK1A

Dual specificity tyrosine-phosphorylation-regulated kinase 1A · Q13627 · DYRK1A on Sugi Atlas →

376,147 patent compounds predicted against DYRK1A, 215,872 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL82928 SCHEMBL82928 0.71 19/20
SCHEMBL81513 SCHEMBL81513 0.56 19/20
SCHEMBL83645 SCHEMBL83645 0.65 18/20
SCHEMBL82655 SCHEMBL82655 0.70 16/20
SCHEMBL81160 SCHEMBL81160 0.54 16/20
SCHEMBL82407 SCHEMBL82407 0.66 15/20
SCHEMBL82789 SCHEMBL82789 0.52 15/20
Purvalanol B Purvalanol B (SCHEMBL27951) 0.71 12/20
SCHEMBL22905 SCHEMBL22905 1.00 11/20
Epigalocatechin Gallate Epigalocatechin Gallate (SCHEMBL35258) 1.00 10/20
Gallocatechin Gallate Gallocatechin Gallate (SCHEMBL49461) 1.00 10/20
SCHEMBL22880 SCHEMBL22880 0.67 10/20
SCHEMBL11827 SCHEMBL11827 0.56 9/20
SCHEMBL10459 SCHEMBL10459 0.55 8/20
SCHEMBL10329 SCHEMBL10329 0.50 8/20
Epicatechin Gallate Epicatechin Gallate (SCHEMBL39046) 1.00 7/20
Epicatechin Gallate Epicatechin Gallate (SCHEMBL39047) 1.00 7/20
SCHEMBL22881 SCHEMBL22881 0.73 7/20
SCHEMBL68662 SCHEMBL68662 0.58 7/20
SCHEMBL79794 SCHEMBL79794 0.41 7/20

Clinical trials — most relevant to DYRK1A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer PHASE3UNKNOWN
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds PHASE2/PHASE3COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer PHASE2RECRUITING
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer PHASE2COMPLETED
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL PHASE2COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy PHASE2ACTIVE_NOT_RECRUITING
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy PHASE2COMPLETED
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System PHASE2WITHDRAWN
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer PHASE2COMPLETED
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations PHASE2COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment PHASE2ACTIVE_NOT_RECRUITING
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy PHASE1RECRUITING
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency PHASE1RECRUITING
Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Abnormal Movements, Cerebellum and Sensorimotor : Oculomotor Study nanCOMPLETED
Cancer Fusion Hybrids and Desmoplasia nanUNKNOWN
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED
LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers nanCOMPLETED
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients nanUNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Efficacy and Safety of Radiofrequency Pallidotomy in the Management of Dystonia nanNOT_YET_RECRUITING
Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer nanRECRUITING
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a DYRK1A binder may also engage these)

ProteinNameSimilarity
Q63470 — 1.000 Q63470 →
Q61214 — 1.000 Q61214 →
Q0IJ08 — 1.000 Q0IJ08 →
Q2TAE3 — 1.000 Q2TAE3 →
A8X4H1 — 0.995 A8X4H1 →
Q9XTF3 — 0.993 Q9XTF3 →
P49657 — 0.993 P49657 →
Q6NSM8 — 0.993 Q6NSM8 →
BMP2K BMP-2-inducible protein kinase 0.992 landscape →
O45797 — 0.992 O45797 →
P24610 — 0.992 P24610 →
Q75D46 — 0.992 Q75D46 →
G5EFF5 — 0.992 G5EFF5 →
Q6P4S6 — 0.991 Q6P4S6 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.991 landscape →
Q7TN99 — 0.991 Q7TN99 →
B3M301 — 0.991 B3M301 →
Q6E3D4 — 0.991 Q6E3D4 →
SIK3 Serine/threonine-protein kinase SIK3 0.991 landscape →
Q91904 — 0.991 Q91904 →
Q297L2 — 0.991 Q297L2 →
O17087 — 0.991 O17087 →
Q5SN53 — 0.991 Q5SN53 →
Q9PVY9 — 0.991 Q9PVY9 →
Q05192 — 0.990 Q05192 →
Q2NL51 — 0.990 Q2NL51 →
Q9W354 — 0.990 Q9W354 →
P14680 — 0.990 P14680 →
B2GUY1 — 0.990 B2GUY1 →
Q8RWH3 — 0.990 Q8RWH3 →